AstraZeneca PLC (NASDAQ:AZN) Announces Strategic Collaboration Agreement With CSPC Pharmaceuticals

AstraZeneca PLC (NASDAQ:AZN) is one of the best long term low volatility stocks to invest in. AstraZeneca PLC (NASDAQ:AZN) announced on January 30 that it is bolstering its weight management portfolio through a new strategic collaboration agreement with CSPC Pharmaceuticals for the advancement of several next-generation therapies for obesity and type 2 diabetes across eight programmes.

The agreement entails the initial progress of four programmes by the companies, leveraging CSPC’s advanced AI-driven peptide drug discovery platform and their proprietary LiquidGel once-monthly dosing platform technology. AstraZeneca PLC (NASDAQ:AZN) reported that it would receive exclusive global rights outside of China to CSPC’s once-monthly injectable weight management portfolio, which includes one clinical-ready asset, SYH2082, a long-acting GLP1R/GIPR agonist progressing into Phase I, and three preclinical programmes with differing mechanisms designed to offer extended therapeutic benefits for people living with obesity and weight-related conditions.

Management further stated that the collaboration complements the company’s existing weight management portfolio, which encompasses an expanding pipeline of next-generation treatments addressing the complexities of obesity and weight-related complications, pursuing multiple modalities and pathways to specialize treatment based on individual needs. This includes elecoglipron (formerly AZD5004), a small molecule oral GLP1RA, AZD9550, a weekly injectable dual GLP-1/glucagon receptor agonist, and AZD6234, a weekly injectable selective amylin receptor agonist (SARA), along with several preclinical assets.

AstraZeneca PLC (NASDAQ:AZN) is a biopharmaceutical company that explores, develops, manufactures, and commercializes prescription medicines. It supplies its products and services to specialty and primary care physicians. AstraZeneca PLC (NASDAQ:AZN) distributes its products and services through local representative offices and distributors.

While we acknowledge the potential of AZN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.